Hologic price target raised to $95 from $93 at Raymond James

Raymond James raised the firm’s price target on Hologic (HOLX) to $95 from $93 and keeps an Outperform rating on the shares. Hologic reported an in line Q4, with revenues slightly ahead due to a 3.1% beat in Diagnostics, though profitability was mixed, the analyst tells investors in a research note. While temporary stop ship headwinds in Skeletal and an IV Fluid shortage in Breast and Surgical related to hurricane create hurdles in 1H25 and creates noise in the story at a high level, the firm notes that the transitory nature of headwinds don’t necessarily indicate a change to the long-term view.